A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Combination product: Trastuzumab + Pertuzumab|DRUG: Placebo
Sponsor: Seagen Inc.
Collaborators: Merck Sharp & Dohme LLC